IL-22+CD4+ T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L

Immunity

Volumn 40, Issue 5, 2014, Pages 772-784

  Kryczek, Ilona ^a   Lin, Yanwei ^a,b   Nagarsheth, Nisha ^a   Peng, Dongjun ^a   Zhao, Lili ^a   Zhao, Ende ^a   Vatan, Linda ^a   Szeliga, Wojciech ^a   Dou, Yali ^a   Owens, Scott ^a   Zgodzinski, Witold ^c   Majewski, Marek ^c   Wallner, Grzegorz ^c   Fang, Jingyuan ^b   Huang, Emina ^d,e   Zou, Weiping ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR6; GAMMA INTERFERON; HISTONE H3; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHYLTRANSFERASE; METHYLTRANSFERASE DOT1L; OCTAMER TRANSCRIPTION FACTOR 4; STAT3 PROTEIN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CANCER TISSUE; CD4+ T LYMPHOCYTE; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME INDUCTION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CCL20; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; HOMEODOMAIN PROTEINS; HT29 CELLS; HUMANS; INTERLEUKINS; METHYLTRANSFERASES; MICE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; RECEPTORS, CCR6; SOXB1 TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR;

EID: 84900459331     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2014.03.010     Document Type: Article

References (59)

1. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., Reinhart T.A., McAllister F., Edeal J., Gaus K., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 2008, 14:275-281.
2. Basu R., O'Quinn D.B., Silberger D.J., Schoeb T.R., Fouser L., Ouyang W.J., Hatton R.D., Weaver C.T. Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity 2012, 37:1061-1075.
3. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
4. Bendall S.C., Stewart M.H., Menendez P., George D., Vijayaragavan K., Werbowetski-Ogilvie T., Ramos-Mejia V., Rouleau A., Yang J., Bossé M., et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells invitro. Nature 2007, 448:1015-1021.
5. Birney E., Stamatoyannopoulos J.A., Dutta A., Guigó R., Gingeras T.R., Margulies E.H., Weng Z., Snyder M., Dermitzakis E.T., Thurman R.E., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816. ENCODE Project Consortium, NISC Comparative Sequencing ProgramNISC Comparative Sequencing Program, Baylor College of Medicine Human Genome Sequencing CenterBaylor College of Medicine Human Genome Sequencing Center, Washington University Genome Sequencing CenterWashington University Genome Sequencing Center, Broad InstituteBroad Institute, Children's Hospital Oakland Research InstituteChildren's Hospital Oakland Research Institute.
6. Brabletz T., Jung A., Spaderna S., Hlubek F., Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
7. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
8. Carpentino J.E., Hynes M.J., Appelman H.D., Zheng T., Steindler D.A., Scott E.W., Huang E.H. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009, 69:8208-8215.
9. Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., Doherty J.M., Mills J.C., Colonna M. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457:722-725.
10. Chang M.J., Wu H., Achille N.J., Reisenauer M.R., Chou C.W., Zeleznik-Le N.J., Hemenway C.S., Zhang W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010, 70:10234-10242.
11. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
12. Cui T.X., Kryczek I., Zhao L., Zhao E., Kuick R., Roh M.H., Vatan L., Szeliga W., Mao Y., Thomas D.G., et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013, 39:611-621.
13. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
14. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory Tcells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
15. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., Johnston L.D., Scott M.P., Smith J.J., Xiao Y., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
16. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
17. Dudakov J.A., Hanash A.M., Jenq R.R., Young L.F., Ghosh A., Singer N.V., West M.L., Smith O.M., Holland A.M., Tsai J.J., et al. Interleukin-22 drives endogenous thymic regeneration in mice. Science 2012, 336:91-95.
18. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory Tcells. Nat. Immunol. 2009, 10:857-863.
19. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
20. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
21. Hanash A.M., Dudakov J.A., Hua G., O'Connor M.H., Young L.F., Singer N.V., West M.L., Jenq R.R., Holland A.M., Kappel L.W., et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37:339-350.
22. Henikoff S., Shilatifard A. Histone modification: cause or cog?. Trends Genet. 2011, 27:389-396.
23. Huber S., Gagliani N., Zenewicz L.A., Huber F.J., Bosurgi L., Hu B., Hedl M., Zhang W., O'Connor W., Murphy A.J., et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012, 491:259-263.
24. Hutchins A.P., Diez D., Takahashi Y., Ahmad S., Jauch R., Tremblay M.L., Miranda-Saavedra D. Distinct transcriptional regulatory modules underlie STAT3's cell type-independent and cell type-specific functions. Nucleic Acids Res. 2013, 41:2155-2170.
25. Jo S.Y., Granowicz E.M., Maillard I., Thomas D., Hess J.L. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011, 117:4759-4768.
26. Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., Harrison O., Powrie F. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J.Exp. Med. 2013, 210:917-931.
27. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J.Exp. Med. 2006, 203:871-881.
28. Kryczek I., Zhao E., Liu Y., Wang Y., Vatan L., Szeliga W., Moyer J., Klimczak A., Lange A., Zou W. Human TH17 Cells Are Long-Lived Effector Memory Cells. Sci Transl Med 2011, 3:104ra100.
29. Kryczek I., Liu S., Roh M., Vatan L., Szeliga W., Wei S., Banerjee M., Mao Y., Kotarski J., Wicha M.S., et al. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 2012, 130:29-39.
30. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
31. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J.Biol. Chem. 2002, 277:33676-33682.
32. Li L., Shaw P.E. Elevated activity of STAT3C due to higher DNA binding affinity of phosphotyrosine dimer rather than covalent dimer formation. J.Biol. Chem. 2006, 281:33172-33181.
33. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
34. Matthews J.R., Sansom O.J., Clarke A.R. Absolute requirement for STAT3 function in small-intestine crypt stem cell survival. Cell Death Differ. 2011, 18:1934-1943.
35. Min J., Feng Q., Li Z., Zhang Y., Xu R.M. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003, 112:711-723.
36. Mohan M., Herz H.M., Takahashi Y.H., Lin C., Lai K.C., Zhang Y., Washburn M.P., Florens L., Shilatifard A. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010, 24:574-589.
37. Nakashima K., Yanagisawa M., Arakawa H., Kimura N., Hisatsune T., Kawabata M., Miyazono K., Taga T. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999, 284:479-482.
38. Ng H.H., Feng Q., Wang H., Erdjument-Bromage H., Tempst P., Zhang Y., Struhl K. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev. 2002, 16:1518-1527.
39. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3:895-902.
40. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
41. Pickert G., Neufert C., Leppkes M., Zheng Y., Wittkopf N., Warntjen M., Lehr H.A., Hirth S., Weigmann B., Wirtz S., et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J.Exp. Med. 2009, 206:1465-1472.
42. Pirker R., Pereira J.R., von Pawel J., Krzakowski M., Ramlau R., Park K., de Marinis F., Eberhardt W.E., Paz-Ares L., Störkel S., et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012, 13:33-42.
43. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
44. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
45. Smith J.J., Deane N.G., Wu F., Merchant N.B., Zhang B., Jiang A., Lu P., Johnson J.C., Schmidt C., Bailey C.E., et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010, 138:958-968.
46. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J.Exp. Med. 2010, 207:1293-1305.
47. Sonnenberg G.F., Monticelli L.A., Alenghat T., Fung T.C., Hutnick N.A., Kunisawa J., Shibata N., Grunberg S., Sinha R., Zahm A.M., et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 2012, 336:1321-1325.
48. Spits H., Cupedo T. Innate lymphoid cells: emerging insights indevelopment, lineage relationships, and function. Annu. Rev. Immunol. 2012, 30:647-675.
49. Thompson C.L., Plummer S.J., Tucker T.C., Casey G., Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control 2010, 21:1165-1170.
50. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper Tcell population that has abundant productionof interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat. Immunol. 2009, 10:864-871.
51. Vermeulen L., de Sousa Melo F., Richel D.J., Medema J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol. 2012, 13:e83-e89.
52. Wang Y., Liu Y., Malek S.N., Zheng P., Liu Y. Targeting HIF1α eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011, 8:399-411.
53. Yamamoto N., Yamamoto S., Inagaki F., Kawaichi M., Fukamizu A., Kishi N., Matsuno K., Nakamura K., Weinmaster G., Okano H., Nakafuku M. Role of Deltex-1 as a transcriptional regulator downstream of the Notch receptor. J.Biol. Chem. 2001, 276:45031-45040.
54. Yang E., Lerner L., Besser D., Darnell J.E. Independent andcooperative activation of chromosomal c-fos promoter by STAT3. J.Biol. Chem. 2003, 278:15794-15799.
55. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer andimmune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
56. Yu W., Chory E.J., Wernimont A.K., Tempel W., Scopton A., Federation A., Marineau J.J., Qi J., Barsyte-Lovejoy D., Yi J., et al. Catalytic siteremodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012, 3:1288.
57. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., Abbas A.R., Modrusan Z., Ghilardi N., de Sauvage F.J., Ouyang W. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 2008, 14:282-289.
58. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.
59. Zou W., Machelon V., Coulomb-L'Hermin A., Borvak J., Nome F., Isaeva T., Wei S., Krzysiek R., Durand-Gasselin I., Gordon A., et al. Stromal-derived factor-1 in human tumors recruits and alters the function ofplasmacytoid precursor dendritic cells. Nat. Med. 2001, 7:1339-1346.